| ¿µ¹® | receptor | ÇÑ±Û | ¼ö¿ëü |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷Áú³» ¶Ç´Â ¼¼Æ÷Ç¥¸é¿¡ Á¸ÀçÇÏ´Â ºÐÀÚ±¸Á¶·Î¼ ƯÀ̹°Áú°ú ¼±ÅÃÀûÀ¸·Î °áÇÕÇÏ¸ç °áÇÕ¿¡ ÀÇÇØ ƯÀÌÇÑ »ý¸®Àû ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. ÆéƼµåÈ£¸£¸ó, ½Å°æÀü´Þ¹°Áú, Ç׿ø, º¸Ã¼, ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼¼Æ÷Ç¥¸é ¼ö¿ëü¿Í ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼¼Æ÷Áú³» ¼ö¿ëü°¡ ÀÖ´Ù. |
||
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
|---|---|
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
| CRL | cell repository line; Certified Record Librarian; complement receptor location; complement receptor ... |
| DR | degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit... |
| CRLR | Calcitonin Receptor-Like Receptor |
|---|---|
| EGF-receptor | Epidermal Growth Factor receptor |
| IRR | Insulin receptor- related receptor |
| alpha 2MR/LRP | alpha (2)-macroglobulin receptor/low density lipoprotein receptor-related protein |
| ORL1 | opioid receptor like receptor |
| receptor | 1. A molecular structure within a cell or on the surface characterised by selective binding of a specific substance and a specific physiologic effect that accompanies the binding, for example, cell surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments and immunoglobulins and cytoplasmic receptors for steroid hormones. 2. A sensory nerve terminal that responds to stimuli of various kinds. (18 Nov 1997) |
|---|---|
| receptor aggregation | Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell. (12 Dec 1998) |
| receptor agonist | A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted. (22 May 1997) |
| receptor downregulation | A phenomenon observed in many cells: following stimulation with a ligand the number of receptors for that ligand on the cell surface diminishes because internalisation exceeds replenishment. Often used very loosely, thus destroying the utility of the term. (18 Nov 1997) |
| receptor mediated endocytosis | Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route. (18 Nov 1997) |
| receptor potential | The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential. (18 Nov 1997) |
| receptor protein | An intracellular protein (or protein fraction) that has a high specific affinity for binding a known stimulus to cellular activity, such as a steroid hormone or adenosine 3',5'-cyclic phosphate. (05 Mar 2000) |
| receptor protein-tyrosine kinase | <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of receptors. Many growth and differentiation factor receptors contain this domain. It is critical for the signal transduction pathways required for mitogenesis, transformation, and cell differentiation. Registry number: EC 2.7.1.- (12 Dec 1998) |
| receptor site | Point of attachment of viruses, hormones, or other activators to cell membranes. (05 Mar 2000) |
| receptor tyrosine kinase | Class of membrane receptors that phosphorylate tyrosine residues. Many play significant roles in development or cell division. Examples: insulin receptor family, c ros receptor, Drosophila sevenless, trk family. (18 Nov 1997) |
| receptor, chemokine | A molecule that receives a chemokine and acts as a dock for a chemokine. Several chemokine receptors are essential co-receptors for HIV. (12 Dec 1998) |
| receptor, visual | The layer of rods and cones, the visual cells, of the retina. (12 Dec 1998) |
| receptor-CD3 complex, antigen, T-cell | Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex. (12 Dec 1998) |
| Receptors for activated C Kinase | Synonym for endosome. (18 Nov 1997) |
| receptors, adrenergic | Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction. (12 Dec 1998) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
|---|---|
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| GABA receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
| gamma aminobutyric acid receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| GAP-1 receptor tyrosine kinase | <enzyme> Similar to rasGTPase-activating proteins; inhibits signaling activity of let-60; amino acid sequence given in first source Registry number: EC 2.7.1.- Synonym: gap-1 gene product, gap-1 protein (26 Jun 1999) |
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, beta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. (12 Dec 1998) |
Synonyms : NF-KappaB Receptor Activator, RANK Protein, Receptor Activator of NF-kappa B, Receptor Activator of NF-kappaB, Receptor Activator of Nuclear Factor-kappaB, TNFRSF11A Protein, TRANCE Receptor, TRANCE-R, Activator, NF-KappaB Receptor, NF KappaB Receptor Activator
Synonyms : Receptor Capping
Synonyms : Receptor Cross Talk, Cross Talk, Receptor, Cross-Talk, Receptor
Synonyms : PTK Receptors, Protein-Tyrosine Kinase Receptor, Receptor Protein-Tyrosine Kinase, Kinase, Receptor Protein-Tyrosine, Kinases, Receptor Protein-Tyrosine, Protein-Tyrosine Kinase Receptors, Protein-Tyrosine Kinase, Receptor, Protein-Tyrosine Kinases, Receptor
Synonyms : Adenosine A1 Receptor, A1 Receptor, Adenosine, A1 Receptors, Adenosine, Receptors, Adenosine A1
| receptor |
a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response sense organ: an organ having nerve endings (in the skin or viscera or eye or ear or nose or mouth) that respond to stimulation
Ãâó: wordnet.princeton.edu/perl/webwn
|
|---|---|
| receptor |
A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell.
Ãâó: www.stjude.org/glossary
|
| receptor |
A molecule that can accept the binding of a ligand.
Ãâó: www.fao.org/docrep/003/X3910E/X3910E21.htm
|
| receptor |
A molecule on the surface of a cell that serves as a recognition or binding site for antigens, antibodies, or other cellular or immunological components.
Ãâó: www.amfar.org/cgi-bin/iowa/bridge.html
|
| receptor |
sensitive component of the ecosystem that reacts to or is influenced by environmental stressors
Ãâó: www.epa.gov/reva/glossary.htm
|
| receptor | an organ having nerve endings (in the skin or viscera or eye or ear or nose or mouth) that respond to stimulation |
|---|---|
| receptor | a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|